Table 2.
Patient characteristics of study population 1.
| Variable | no-HF (n = 60) | HF (n = 40) |
|---|---|---|
| Age, years | 70 ± 8 | 72 ± 13 |
| Gender, male | 30 (50%) | 20 (50%) |
| SBP, mmHg | 142 ± 16 | 133 ± 21* |
| BNP, pg/ml | 23 (13:36) | 107 (45:231)*** |
| Diabetes Mellitus | 8 (13%) | 11 (28%) |
| Hypertension | 42 (70%) | 18 (45%)* |
| Medications | ||
| RAAS Inhibitor | 32 (53%) | 35 (88%)*** |
| Βeta-Blocker | 16 (27%) | 30 (75%)*** |
| Statin | 42 (70%) | 20 (50%)* |
| Diuretic | 21 (35%) | 30 (75%)*** |
| Echocardiography | ||
| EF, % | 68 ± 9 | 60 ± 8*** |
| E/E’ | 8.8 ± 3.1 | 9.6 ± 3.5 |
| LVMI, g/m2 | 97 ± 23 | 127 ± 37*** |
| LAVI, mls/m2 | 23 ± 4 | 46 ± 2*** |
Values are mean ± SD, mean (25th:75th percentiles) or n (%). SBP, systolic blood pressure; RAAS Inhibitor, renin angiotensin system inhibitor; EF, ejection fraction; LVMI, left ventricular mass index; LAVI, left atrial volume index. P-value <0.05 is significant and depicted with *p < 0.01 – with **; and p < 0.001 – with ***.